Patents by Inventor Robert G. K. Donald

Robert G. K. Donald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF
    Publication number: 20130244307
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Application
    Filed: March 22, 2013
    Publication date: September 19, 2013
    Applicant: WYETH LLC
    Inventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Terri L. Mininni, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
  • Compositions relating to a mutant toxin and methods thereof
    Patent number: 8481692
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: July 9, 2013
    Assignee: Wyeth LLC
    Inventors: Maninder K. Sidhu, Annaliesa Sybil Anderson, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
  • COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF
    Publication number: 20120269841
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Application
    Filed: April 20, 2012
    Publication date: October 25, 2012
    Applicant: WYETH LLC
    Inventors: Maninder K. Sidhu, Annaliesa Sybil Anderson, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Terri L. Mininni, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
  • Polynucleotides encoding coccidian parasite casein kinase I, a chemotherapeutic target for antiprotozoal agents
    Patent number: 7671181
    Abstract: Isolated nucleic acid molecules encoding coccidian casein kinase I, CKI, enzymes from the species Eimeria tenella and Toxoplasma gondii are disclosed. The isolation of these coccidian CKI cDNA sequences results in the disclosure of purified forms of E. tenella and T. gondii CKI proteins, recombinant vectors and recombinant hosts which express coccidian CKI.
    Type: Grant
    Filed: January 12, 2005
    Date of Patent: March 2, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert G. K. Donald, Paul Liberator, Xiaotian Zhong
  • Coccidian Parasite Casein Kinase I as a Chemotherapeutic Target for Antiprotozoal Agents
    Publication number: 20080280313
    Abstract: Isolated nucleic acid molecules encoding coccidian casein kinase I, CKI, enzymes from the species Eimeria tenella and Toxoplasma gondii are disclosed. The isolation of these coccidian CKI cDNA sequences results in the disclosure of purified forms of E. tenella and T. gondii CKI proteins, recombinant vectors and recombinant hosts which express coccidian CKI.
    Type: Application
    Filed: January 12, 2005
    Publication date: November 13, 2008
    Inventors: Robert G.K. Donald, Paul Liberator, Xiaotian Zhong